Status:
COMPLETED
Observational Study of NovoNorm® in Subjects With Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 diabetes
Exclusion
Key Trial Info
Start Date :
August 30 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 25 2005
Estimated Enrollment :
5841 Patients enrolled
Trial Details
Trial ID
NCT01498913
Start Date
August 30 2001
End Date
March 25 2005
Last Update
February 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Seoul, South Korea, 137-920